MedTrace Logo

Afatinib in NSCLC With HER2 Mutation

NCT02369484 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-08-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the control of disease in pretreated patients with advanced non small cell lung cancer (NSCLC) harbouring HER2 exon 20 mutations as well as the safety and tolerability (how severe the side effects are) of the treatment with afatinib.

Conditions

Interventions

DRUG

Afatinib

40mg p.o./ day until documented progression or unacceptable toxicity

Sponsors & Collaborators

  • ETOP IBCSG Partners Foundation

    lead NETWORK

Principal Investigators

  • Solange Peters, MD-PhD · Centre Hospitalier Universitaire Vaudois (CHUV); Lausanne, Switzerland

  • Rafal Dziadziuszko, MD · Medical University of Gdansk, Gdansk, Poland

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-16
Primary Completion
2017-09-15
Completion
2017-09-15

Countries

  • Germany
  • Netherlands
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02369484 on ClinicalTrials.gov